Total Payments
$407,233
2024 Payments
$175,733
Companies
10
Transactions
143
Medicare Patients
3,190
Medicare Billing
$222,411
Payment Breakdown by Category
Research$360,077 (88.4%)
Consulting$44,328 (10.9%)
Travel$1,516 (0.4%)
Food & Beverage$1,312 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $360,077 | 111 | 88.4% |
| Consulting Fee | $44,328 | 4 | 10.9% |
| Travel and Lodging | $1,516 | 13 | 0.4% |
| Food and Beverage | $1,312 | 15 | 0.3% |
Payments by Type
Research
$360,077
111 transactions
General
$47,156
32 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $175,733 | 2 | $0 (2024) |
| Kowa Research Institute, Inc. | $153,425 | 33 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $42,692 | 3 | $0 (2022) |
| The Medicines Company | $24,413 | 84 | $0 (2018) |
| Swedish Orphan Biovitrum AB | $7,578 | 5 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,636 | 1 | $0 (2020) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $897.75 | 8 | $0 (2023) |
| Novo Nordisk AS | $734.42 | 4 | $0 (2017) |
| Boston Scientific Corporation | $90.04 | 2 | $0 (2019) |
| Amgen Inc. | $35.09 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $175,733 | 2 | Eli Lilly and Company ($175,733) |
| 2023 | $932.84 | 9 | NOVARTIS PHARMACEUTICALS CORPORATION ($897.75) |
| 2022 | $42,692 | 3 | AstraZeneca Pharmaceuticals LP ($42,692) |
| 2020 | $2,062 | 2 | Bayer HealthCare Pharmaceuticals Inc. ($1,636) |
| 2019 | $80,011 | 11 | Kowa Research Institute, Inc. ($79,921) |
| 2018 | $96,846 | 95 | Kowa Research Institute, Inc. ($72,433) |
| 2017 | $8,957 | 21 | Swedish Orphan Biovitrum AB ($7,152) |
All Payment Transactions
143 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $163,296.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | ||||||
| 03/21/2024 | Eli Lilly and Company | — | — | In-kind items and services | $12,436.50 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | ||||||
| 05/20/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $184.52 | General |
| 05/20/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $48.92 | General |
| 04/05/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $35.09 | General |
| Category: Cardiology | ||||||
| 03/11/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $223.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/11/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $221.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/11/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | LEQVIO (Drug) | Travel and Lodging | In-kind items and services | $55.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/11/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | LEQVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $31.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/11/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/10/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $124.86 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/26/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $32,488.50 | General |
| 09/06/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $9,666.00 | General |
| 06/21/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 11/08/2020 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Consulting Fee | Cash or cash equivalent | $1,636.00 | General |
| 04/27/2020 | Swedish Orphan Biovitrum AB | KINERET (Drug) | — | Cash or cash equivalent | $426.00 | Research |
| Study: SOBI.ANAKIN-401 • Category: IMMUNOLOGY | ||||||
| 12/16/2019 | Kowa Research Institute, Inc. | — | — | Cash or cash equivalent | $5,243.40 | Research |
| Study: K-877-302 | ||||||
| 11/22/2019 | Kowa Research Institute, Inc. | — | — | Cash or cash equivalent | $14,802.30 | Research |
| Study: K-877-302 | ||||||
| 10/25/2019 | Kowa Research Institute, Inc. | — | — | Cash or cash equivalent | $1,797.30 | Research |
| Study: K-877-302 | ||||||
| 10/01/2019 | Kowa Research Institute, Inc. | — | — | Cash or cash equivalent | $18,226.80 | Research |
| Study: K-877-302 | ||||||
| 09/11/2019 | Boston Scientific Corporation | SPECTRA WAVEWRITER (Device) | Food and Beverage | In-kind items and services | $52.29 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/18/2019 | Kowa Research Institute, Inc. | — | — | Cash or cash equivalent | $11,618.10 | Research |
| Study: K-877-302 | ||||||
| 07/02/2019 | Boston Scientific Corporation | GENERAL PAIN MANAGEMENT (Device) | Food and Beverage | In-kind items and services | $37.75 | General |
| Category: PAIN MANAGEMENT | ||||||
| 05/22/2019 | Kowa Research Institute, Inc. | — | — | Cash or cash equivalent | $3,858.30 | Research |
| Study: K-877-302 | ||||||
| 05/06/2019 | Kowa Research Institute, Inc. | — | — | Cash or cash equivalent | $16,179.30 | Research |
| Study: K-877-302 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | Eli Lilly and Company | $175,733 | 2 |
| K-877-302 | Kowa Research Institute, Inc. | $152,354 | 20 |
| INCLISIRAN FOR PARTICIPANTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL ORION-10 | The Medicines Company | $24,413 | 84 |
| Sobi.anakin-401 | Swedish Orphan Biovitrum AB | $7,152 | 4 |
| SOBI.ANAKIN-401 | Swedish Orphan Biovitrum AB | $426.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 595 | 1,132 | $78,838 | $45,632 |
| 2022 | 10 | 685 | 1,316 | $93,719 | $52,429 |
| 2021 | 11 | 911 | 1,634 | $109,442 | $62,000 |
| 2020 | 12 | 999 | 1,805 | $110,382 | $62,351 |
Total Patients
3,190
Total Services
5,887
Medicare Billing
$222,411
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 95 | 219 | $29,565 | $18,378 | 62.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 103 | 164 | $30,370 | $18,273 | 60.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 114 | 411 | $4,110 | $3,452 | 84.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 51 | $4,885 | $2,790 | 57.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 22 | 36 | $2,180 | $1,368 | 62.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 81 | 82 | $4,920 | $765.81 | 15.6% |
| 81002 | Urinalysis, manual test | Office | 2023 | 108 | 130 | $2,340 | $443.30 | 18.9% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2023 | 37 | 39 | $468.00 | $161.85 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 111 | 262 | $35,430 | $21,552 | 60.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 110 | 175 | $32,395 | $21,036 | 64.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 55 | $5,225 | $3,393 | 64.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 27 | 45 | $2,700 | $1,849 | 68.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 119 | 467 | $4,670 | $1,383 | 29.6% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 36 | 36 | $4,500 | $1,348 | 30.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 76 | 77 | $4,620 | $719.02 | 15.6% |
| 81002 | Urinalysis, manual test | Office | 2022 | 110 | 141 | $2,538 | $484.91 | 19.1% |
| 69210 | Removal of impacted ear wax | Office | 2022 | 15 | 15 | $1,125 | $483.78 | 43.0% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2022 | 40 | 43 | $516.00 | $179.97 | 34.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 127 | 286 | $38,548 | $24,318 | 63.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 130 | 206 | $37,925 | $23,452 | 61.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 50 | 70 | $6,703 | $4,559 | 68.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 35 | 53 | $3,180 | $2,149 | 67.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 145 | 534 | $5,340 | $1,602 | 30.0% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Office | 2021 | 41 | 41 | $5,125 | $1,583 | 30.9% |
| 90756 | Vaccine for influenza derived from cell cultures for injection into muscle, quadrivalent, antibiotic free, 0.5ml dosage | Office | 2021 | 55 | 55 | $1,650 | $1,560 | 94.6% |
About Dr. Alan Miller, M.D
Dr. Alan Miller, M.D is a Internal Medicine healthcare provider based in Peachtree Corners, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508815606.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Miller, M.D has received a total of $407,233 in payments from pharmaceutical and medical device companies, with $175,733 received in 2024. These payments were reported across 143 transactions from 10 companies. The most common payment nature is "" ($360,077).
As a Medicare-enrolled provider, Miller has provided services to 3,190 Medicare beneficiaries, totaling 5,887 services with total Medicare billing of $222,411. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Peachtree Corners, GA
- Active Since 05/08/2006
- Last Updated 05/31/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1508815606
Products in Payments
- Kineret (Drug) $7,152
- Non-Covered $1,636
- LEQVIO (Drug) $664.31
- KINERET (Drug) $426.00
- SPECTRA WAVEWRITER (Device) $52.29
- GENERAL PAIN MANAGEMENT (Device) $37.75
- Repatha (Biological) $35.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.